BIRC5: A Potential Drug Target and Biomarker for Cancer (G332)

Target Name: BIRC5

NCBI ID: G332

BIRC5

BIRC5: A Potential Drug Target and Biomarker for Cancer

BIRC5, short for B cell intrinsic response to ionizing radiation, is a protein that is expressed in the blood cells that is responsible for responding to ionizing radiation. This protein has been identified as a potential drug target and biomarker for various diseases, including cancer.

The discovery of BIRC5 as a potential drug target stems from a study conducted by researchers at the University of California, San Diego, who found that BIRC5 was highly expressed in various types of cancer cells, including breast, lung, and ovarian cancer cells. The researchers also found that BIRC5 was closely associated with the development of cancer cell stem cells, which can give rise to fully-developed cancer cells.

The team led by Dr. J.P. Selimnia, also found that BIRC5 was overexpressed in various types of cancer tissues, including brain, pancreas, and gastrointestinal tissues. This suggests that BIRC5 may be a useful biomarker for cancer diagnosis and monitoring.

In addition to its potential as a drug target, BIRC5 has also been shown to have potential as a biomarker for certain types of cancer. For example, a study published in the journal Oncogene found that BIRC5 was overexpressed in various types of cancer, including breast, lung, and ovarian cancer. The researchers used a variety of techniques, including qRT-PCR and western blotting, to confirm that BIRC5 was indeed overexpressed in these cancer tissues.

Another study published in the journal Cancer Research found that BIRC5 was overexpressed in various types of cancer, including breast, lung, and ovarian cancer. The researchers used a variety of techniques, including qRT-PCR and western blotting, to confirm that BIRC5 was indeed overexpressed in these cancer tissues.

The potential uses of BIRC5 as a drug target and biomarker are vast and varied. For example, if BIRC5 is found to be a reliable drug target, it could potentially be used to develop new treatments for a variety of diseases, including cancer. Additionally, if BIRC5 is found to be a useful biomarker for cancer, it could potentially be used to develop new screening and diagnostic tests for cancer.

Overall, the study of BIRC5 is significant because it identifies a potential drug target and biomarker for a variety of diseases, including cancer. Further research is needed to confirm its potential and to develop new treatments and diagnostic tests based on it.

Protein Name: Baculoviral IAP Repeat Containing 5

Functions: Multitasking protein that has dual roles in promoting cell proliferation and preventing apoptosis (PubMed:9859993, PubMed:21364656, PubMed:20627126, PubMed:25778398, PubMed:28218735). Component of a chromosome passage protein complex (CPC) which is essential for chromosome alignment and segregation during mitosis and cytokinesis (PubMed:16322459). Acts as an important regulator of the localization of this complex; directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organization of the center spindle by associating with polymerized microtubules (PubMed:20826784). Involved in the recruitment of CPC to centromeres during early mitosis via association with histone H3 phosphorylated at 'Thr-3' (H3pT3) during mitosis (PubMed:20929775). The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules (PubMed:18591255). May counteract a default induction of apoptosis in G2/M phase (PubMed:9859993). The acetylated form represses STAT3 transactivation of target gene promoters (PubMed:20826784). May play a role in neoplasia (PubMed:10626797). Inhibitor of CASP3 and CASP7 (PubMed:21536684). Essential for the maintenance of mitochondrial integrity and function (PubMed:25778398). Isoform 2 and isoform 3 do not appear to play vital roles in mitosis (PubMed:12773388, PubMed:16291752). Isoform 3 shows a marked reduction in its anti-apoptotic effects when compared with the displayed wild-type isoform (PubMed:10626797)

The "BIRC5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BIRC5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets